Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cis-regulatory Sequences02:02

Cis-regulatory Sequences

11.6K
Cis-regulatory sequences are short fragments of non-coding DNA that are present on the same chromosomes as the genes that they regulate. These fragments serve as binding sites for transcriptional regulators, proteins that are responsible for controlling gene transcription and differential gene expression across cell types in eukaryotes. Cis-regulatory sequences can be close to the gene of interest or thousands of bases away in the DNA sequence; however, those sequences that are further away are...
11.6K
Cis-regulatory Sequences02:02

Cis-regulatory Sequences

4.1K
4.1K
Benefits of Self-Esteem01:25

Benefits of Self-Esteem

194
Self-esteem—an individual's overall evaluation of their worth—plays a complex role in psychological functioning and well-being. It is often associated with many positive traits, such as confidence, optimism, and perseverance. Individuals with high self-esteem typically experience better sleep, manage peer pressure more effectively, and report greater life satisfaction. Conversely, low self-esteem has been consistently linked with increased risks of depression, anxiety, and poor...
194
Decision Making01:20

Decision Making

943
Decision-making is a fundamental cognitive process that involves evaluating alternatives and selecting among them. This process can range from simple choices, such as deciding what to wear, to complex decisions, like choosing a major in college or a career path. The complexity of the decision often dictates the approach we use, which can be broadly categorized into two types: automatic and controlled decision-making.
Automatic decision-making is fast, intuitive, and relies on gut feelings...
943
Relative Risk01:12

Relative Risk

2.0K
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
2.0K
Global Regulatory Systems01:28

Global Regulatory Systems

626
Global regulatory systems in bacteria enable rapid and coordinated responses to environmental changes by integrating sensory inputs with gene expression, ensuring efficient adaptation to fluctuating conditions. Key global regulatory mechanisms include regulons, two-component systems, sigma factors, and secondary messengers.Regulons and Global RegulatorsA regulon is a collection of genes and operons controlled by a common global regulator. These regulators enable bacteria to prioritize resource...
626

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Supply and Demand in the Mathematics of Rare Disease Drug Development: Why Choosing the Right Model Is Crucial.

Clinical and translational science·2026
Same author

The Placebo Effect in Rare Disease Clinical Trials: Measurement, Impact, and Statistical Approaches for Patient-as-Own-Control Designs.

Clinical and translational science·2026
Same author

The Future of Biologics: Lessons from Hatch-Waxman.

Therapeutic innovation & regulatory science·2026
Same author

A novel real-world data methodology for lymphoma outcome classification: the real-world Lugano study.

Journal of comparative effectiveness research·2026
Same author

Response to the FDA's proposed pathway for individualized genetic therapies.

Molecular therapy : the journal of the American Society of Gene Therapy·2025
Same author

A Threat to Evidence-Based Vaccine Policy and Public Health Security at the FDA.

The New England journal of medicine·2025

Related Experiment Video

Updated: Jan 26, 2026

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
07:05

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Published on: September 10, 2018

6.4K

Using a Benefit-Risk Analysis Approach to Capture Regulatory Decision Making: Melanoma.

G K Raju1,2, Karthik Gurumurthi1, Reuben Domike1,3

  • 1Light Pharma, Inc., Cambridge, Massachusetts, USA.

Clinical Pharmacology and Therapeutics
|April 18, 2019
PubMed
Summary
This summary is machine-generated.

Drug regulators evaluate melanoma drug benefits and risks for FDA approval. This study quantified these factors from clinical trials, finding decisions aligned with the data.

More Related Videos

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.8K
Author Spotlight: Innovations in iTUG Test for Enhanced Risk Assessment and Cognitive Insights
05:26

Author Spotlight: Innovations in iTUG Test for Enhanced Risk Assessment and Cognitive Insights

Published on: October 25, 2024

1.7K

Related Experiment Videos

Last Updated: Jan 26, 2026

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
07:05

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Published on: September 10, 2018

6.4K
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.8K
Author Spotlight: Innovations in iTUG Test for Enhanced Risk Assessment and Cognitive Insights
05:26

Author Spotlight: Innovations in iTUG Test for Enhanced Risk Assessment and Cognitive Insights

Published on: October 25, 2024

1.7K

Area of Science:

  • Oncology
  • Pharmacoeconomics
  • Regulatory Science

Background:

  • Drug regulators assess benefits and risks for drug approvals.
  • Melanoma drug development involves complex decision-making processes.

Purpose of the Study:

  • To quantify the benefits and risks of melanoma drugs approved by the US Food and Drug Administration (FDA).
  • To analyze the consistency between quantified benefits and risks and FDA decision outcomes.

Main Methods:

  • Analysis of 25 FDA decisions for melanoma drugs based on clinical trial data (1999-2017).
  • Quantification of drug benefits and risks relative to comparators on a common scale.
  • Sensitivity analysis using vemurafenib to assess uncertainty.

Main Results:

  • Quantified benefits and risks were consistently aligned with FDA approval decisions.
  • A common scale facilitated direct comparison of benefits and risks across diverse trials.
  • Sensitivity analysis demonstrated the magnitude of uncertainty in quantitative assessments.

Conclusions:

  • The study validates a quantitative approach to assessing drug benefits and risks in regulatory decision-making.
  • FDA approval outcomes for melanoma drugs correlate with analyzed clinical trial data.
  • This framework can support objective drug approval evaluations.